Opinion

Video

An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

Current Time 0:00
Duration 2:30
Loaded: 0%
Stream Type LIVE
Remaining Time 2:30
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    1 expert in this video
    Using Ultrasensitive PSA Assays in Routine Practice
    1 expert in this video
    Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    1 expert in this video
    Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
    1 expert in this video
    Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tailoring prostate cancer care for older adults
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: New strategies emerge for metastatic prostate cancer
    Related Content
    Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
    June 4th 2025

    ARANOTE: Darolutamide improves HRQoL in mHSPC

    Benjamin P. Saylor
    Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    FDA approves darolutamide in metastatic castration-sensitive prostate cancer
    June 3rd 2025

    FDA approves darolutamide in metastatic castration-sensitive prostate cancer

    Hannah Clarke
    The approval is supported by data from the pivotal phase 3 ARANOTE trial.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Alicia Morgans, MD, MPH
    June 3rd 2025

    Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

    Benjamin P. Saylor
    “As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
    Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
    June 2nd 2025

    Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC

    Hannah Clarke
    Data also showed a positive trend in overall survival.
    © 2025 MJH Life Sciences

    All rights reserved.